[144] BridgeBio Pharma, Inc. SEC Filing

Rhea-AI Filing Summary

BridgeBio Pharma (BBIO) filed a Form 144 notifying a proposed sale of 26,156 common shares acquired as restricted stock units on 08/16/2025. The filing lists Morgan Stanley Smith Barney LLC as the broker and shows an aggregate market value of $1,279,289.96 for the proposed sale, with the shares to be sold on 08/20/2025 on NASDAQ. The securities to be sold were granted and acquired from the issuer on 08/16/2025 and paid on that date, identified as Restricted Stock Units. The filing also reports multiple prior Rule 10b5-1 sales during July and August 2025, each for 20,000 shares executed by related trusts, totaling eight reported transactions.

Insights

Securities Analyst

TL;DR: Routine insider disposition of RSUs via broker; prior scheduled 10b5-1 sales were executed across July–August 2025.

The Form 144 documents a proposed sale of 26,156 common shares that were acquired as Restricted Stock Units on 08/16/2025, with Morgan Stanley Smith Barney LLC named as the broker and an indicated aggregate market value of $1,279,289.96. The filing is explicit about the acquisition date and nature of the securities and the intended sale date of 08/20/2025. The record also lists multiple 10b5-1 plan sales in July and August 2025, each for 20,000 shares, reported with gross proceeds for each transaction. This content describes compliant, scheduled insider transactions rather than new corporate disclosures or financial performance data.

Compliance/Risk Analyst

TL;DR: Disclosure appears procedural and consistent with Rule 144 and 10b5-1 reporting requirements.

The notice identifies the securities as RSUs acquired from the issuer and specifies broker details, dates, and amounts, satisfying the form's required fields. The inclusion of multiple 10b5-1 sales for related trust accounts during July and August 2025 indicates prior planned dispositions were executed and disclosed. The filing contains the standard attestation language regarding absence of undisclosed material information. No additional regulatory or compliance issues are stated in the document.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	26156	1279289.96	191168504	08/20/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/16/2025	Restricted Stock Units	Issuer			26156	08/16/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for KUMAR HALDEA REVOCABLETRUST U/A DTD 12/19/2018 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	08/08/2025	20000	924414.00
10b5-1 Sales for NEIL KUMAR & SHRUTI HALDEA CO-TTEEKUMAR HALDEA FAMILY IRREVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	08/08/2025	20000	924414.00
10b5-1 Sales for KUMAR HALDEA REVOCABLETRUST U/A DTD 12/19/2018 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	08/07/2025	20000	909060.00
10b5-1 Sales for NEIL KUMAR & SHRUTI HALDEA CO-TTEEKUMAR HALDEA FAMILY IRREVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	08/07/2025	20000	909060.00
10b5-1 Sales for KUMAR HALDEA REVOCABLETRUST U/A DTD 12/19/2018 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	07/02/2025	20000	854536.00
10b5-1 Sales for NEIL KUMAR & SHRUTI HALDEA CO-TTEEKUMAR HALDEA FAMILY IRREVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	07/02/2025	20000	854514.00
10b5-1 Sales for KUMAR HALDEA REVOCABLETRUST U/A DTD 12/19/2018 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	07/01/2025	20000	850680.00
10b5-1 Sales for NEIL KUMAR & SHRUTI HALDEA CO-TTEEKUMAR HALDEA FAMILY IRREVOCABLE TRUST 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	07/01/2025	20000	850720.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does BridgeBio (BBIO) report on this Form 144?

BridgeBio reports a proposed sale of 26,156 common shares acquired as Restricted Stock Units on 08/16/2025, to be sold on 08/20/2025 on NASDAQ.

Who is the broker handling the proposed sale in the BBIO Form 144?

Morgan Stanley Smith Barney LLC is named as the broker with address listed in the filing.

What is the aggregate market value and number of shares for the proposed sale?

Aggregate market value $1,279,289.96 for 26,156 shares as stated in the filing.

Were there prior sales of BBIO shares reported in the filing?

Yes. The filing lists eight prior 10b5-1 sales in July–August 2025, each for 20,000 shares, reported with gross proceeds per transaction.

When were the shares to be sold originally acquired?

The shares were acquired on 08/16/2025 and are identified as Restricted Stock Units from the issuer.